Ligand Pharmaceuticals (LGND) Other Non Operating Income (2010 - 2026)
Ligand Pharmaceuticals recorded quarterly Other Non Operating Income of -$1.2 million in Q1 2026, down 179.23% quarter-over-quarter from $1.5 million in Q4 2025, and up 53.02% year-over-year from -$767879.5 in Q1 2025.
Ligand Pharmaceuticals' Other Non Operating Income history runs 17 years deep, the most recent figure standing at -$1.2 million for Q1 2026.
- In Q1 2026, Other Non Operating Income rose 53.02% year-over-year to -$1.2 million; the TTM figure through Mar 2026 stood at $2.5 million (up 105.55% YoY), while the FY2025 annual figure was -$89000.0, up 99.41% from the prior year.
- Other Non Operating Income came in at -$1.2 million for Q1 2026 at Ligand Pharmaceuticals, down from $1.5 million in the prior quarter.
- In the past five years, Other Non Operating Income ranged from a high of $4.6 million in Q4 2023 to a low of -$33.5 million in Q2 2024.
- A 5-year average of -$2.5 million and a median of -$58000.0 in 2022 frame the typical range for Other Non Operating Income.
- Across the five-year window, Other Non Operating Income jumped 676.29% in 2023 and plunged 3739.98% in 2024, its largest moves.
- Ligand Pharmaceuticals' Other Non Operating Income stood at -$793000.0 in 2022, then surged by 676.29% to $4.6 million in 2023, then slumped by 131.73% to -$1.4 million in 2024, then surged by 202.28% to $1.5 million in 2025, then slumped by 179.23% to -$1.2 million in 2026.
- According to Business Quant data, Other Non Operating Income over the past three periods registered -$1.2 million, $1.5 million, and $833000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Ligand Pharmaceuticals | 4.61 Bn | 3.83 Bn | 48.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.18 Mn |
| Dec 31, 2025 | 1.48 Mn |
| Sep 30, 2025 | 833,000.00 |
| Jun 30, 2025 | 1.37 Mn |
| Mar 31, 2025 | -2.50 Mn |
| Dec 31, 2024 | -1.45 Mn |
| Sep 30, 2024 | -7.81 Mn |
| Jun 30, 2024 | -33.52 Mn |
| Dec 31, 2023 | 4.57 Mn |
| Jun 30, 2023 | -873,000.00 |
| Dec 31, 2022 | -793,000.00 |
| Sep 30, 2022 | 677,000.00 |
| Jun 30, 2022 | 2.05 Mn |
| Mar 31, 2022 | 2.26 Mn |
| Dec 31, 2021 | 5.52 Mn |
| Sep 30, 2021 | 1.89 Mn |
| Jun 30, 2021 | -924,000.00 |
| Mar 31, 2021 | -6.48 Mn |
| Dec 31, 2020 | -1.88 Mn |
| Sep 30, 2020 | -219,000.00 |
| Jun 30, 2020 | 1.80 Mn |
| Mar 31, 2020 | 356,000.00 |
| Dec 31, 2019 | -4.58 Mn |
| Sep 30, 2019 | 181,000.00 |
| Jun 30, 2019 | 890,000.00 |
| Mar 31, 2019 | 1.87 Mn |
| Dec 31, 2018 | -854,000.00 |
| Sep 30, 2018 | -808,000.00 |
| Jun 30, 2018 | -3.87 Mn |
| Mar 31, 2018 | -221,000.00 |
| Dec 31, 2017 | 3.79 Mn |
| Sep 30, 2017 | -581,000.00 |
| Jun 30, 2017 | -455,000.00 |
| Mar 31, 2017 | 141,000.00 |
| Dec 31, 2016 | -2.72 Mn |
| Sep 30, 2016 | 1.22 Mn |
| Jun 30, 2016 | 501,000.00 |
| Mar 31, 2016 | 391,000.00 |
| Dec 31, 2015 | -121,000.00 |
| Sep 30, 2015 | 1.49 Mn |
| Jun 30, 2015 | 850,000.00 |
| Mar 31, 2015 | -447,000.00 |
| Dec 31, 2014 | 543,000.00 |
| Sep 30, 2014 | 505,000.00 |
| Jun 30, 2014 | 1.38 Mn |
| Mar 31, 2014 | -754,000.00 |
| Dec 31, 2013 | -132,000.00 |
| Sep 30, 2013 | -119,000.00 |
| Jun 30, 2013 | 2,000.00 |
| Mar 31, 2013 | 191,000.00 |
| Dec 31, 2012 | 244,000.00 |
| Sep 30, 2012 | 15,000.00 |
| Jun 30, 2012 | 2,000.00 |
| Mar 31, 2012 | 254,000.00 |
| Dec 31, 2011 | 556,000.00 |
| Sep 30, 2011 | -10,000.00 |
| Jun 30, 2011 | 32,000.00 |
| Mar 31, 2011 | 48,000.00 |
| Dec 31, 2010 | 1.90 Mn |
| Sep 30, 2010 | 1.73 Mn |
| Jun 30, 2010 | 168,000.00 |